Drug Delivery
Versatile Nanomedicine Production
Nucleic Acid Lipid Nanoparticles
Polymeric Nanoparticles
Liposomes
Emulsions
Microfluidic technologies allow the production of a variety of nanomedicine carrier types, allowing researchers to concentrate on the
development of effective APIs
then a vaccine would only be available to innocu- late the survivors, which is futile. If, instead, a generic carrier particle was already available and ready for manufacture, then efforts could concen- trate on identifying and producing the correct anti- gen, speeding up the entire process. While the mutation rate of the HIV virus may present a sig- nificant challenge to this strategy, it could be effec- tive against other viruses of international concern – such as Zika – providing a rapid vaccine develop- ment platform.
Summary
The commercial availability of microfluidic plat- forms aimed specifically at drug formulation is helping to lower the barriers to nanomedicine research. Implementation of this technology elimi- nates the need for in-house microfluidics expertise and extensive process development, helping to accelerate research and development timelines and providing a clear roadmap from early research to end product. By working with these technologies, researchers can spend their time designing and planning their experiments, solving problems and asking the big questions, rather than making nanoparticles.
DDW
Professor Yvonne Perrie, Strathclyde Institute of Pharmacy and Biomedical Sciences. Professor Perrie’s multi-disciplinary research focuses on the development of drug delivery systems to facilitate the delivery of drugs and vaccines, thus providing practical solutions for current healthcare prob- lems. Following her PhD investigating the role of liposomes for drug delivery, she worked for newly-
22 Drug Discovery World Fall 2017
established drug delivery company Lipoxen Technologies Ltd before returning to academia to set up her own research group.
Dr Euan Ramsay is COO of Precision NanoSystems. Dr Ramsay is a co-founder of Precision NanoSystems and has helped lead the company’s R&D and operational developments since inception. Prior to Precision NanoSystems he worked at the Canadian Centre for Drug Research and Development. Dr Ramsay has a degree in pharmacy and a PhD in gene therapy.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
